Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.32 USD
Change Today -0.12 / -3.49%
Volume 1.0M
IDRA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

idera pharmaceuticals inc (IDRA) Key Developments

Idera Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse B-Cell Lymphoma

Idera Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL). Idera is currently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. Preclinical studies have shown that in B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling. The objectives of the trial are to evaluate the compound's safety, tolerability and clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously.

Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM

Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer and Director.

Idera Pharmaceuticals, Inc. Announces Resignation of Louis Brenner as Senior Vice President and Chief Medical Officer, Effective April 3, 2015

On March 17, 2015, Louis Brenner, M.D. resigned his positions as Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3, 2015.

Idera Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Idera Pharmaceuticals, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net loss applicable to common stockholders was $12.0 million, or $0.14 per diluted share, compared to $6.4 million or $0.10 per diluted share, for the same period in 2013. Alliance revenue was $2,000 against $4,000 a year ago. Loss from operations was $11,929,000 against $6,072,000 a year ago. For the year, net loss applicable to common stockholders was $39.2 million or $0.47 per diluted share, compared to $21.1 million, or $0.48 per diluted share, for the same period in 2013. Alliance revenue was $73,000 against $47,000 a year ago. Loss from operations was $38,752,000 against $18,169,000 a year ago.

Idera Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM

Idera Pharmaceuticals, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $3.32 USD -0.12

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies
 

Industry Analysis

IDRA

Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,130.7x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,976.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.